Death receptor 5 (DR5) can inhibit malignant proliferation via TRAIL‐induced apoptosis in many cancers. Here, we examined the expression and sublocalization of DR5 in gastric cancer, as well as its effects on clinical prognosis and cellular processes. Our analysis included a cohort of 240 gastric cancer patients. Bioinformatic analysis showed a significant correlation between DR5 and DNA replication, tumor mutation burden (TMB), and tumor stemness. Unlike death receptor 4 (DR4TRAIL‐R1), DR5 was expressed in the the cytoplasm and nucleus, and was found to be positively correlated with lymphovascular invasion, lymph node metastasis, and TNM stage. Patients with positive DR5 had worse overall survival (OS) (p=0.006). The multivariate Cox model showed that DR5 is an independent poor prognostic factor (Hazard Ratio =1.693). Furthermore, knockdown of DR5 inhibited aggressive behaviors including proliferation and metastasis in gastric cancer cells, and inhibited lung metastasis in vivo. In summary, nuclear localization of DR5 expression is a poor prognosis factor in gastric cancer, and promotes growth, invasion, and metastasis of tumor cells in vitro and in vivo.